Cat. No. 5565
Alternative Names: PAI 039, tiplasinin
Chemical Name: α-Oxo-1-(phenylmethyl)-5-[4-(trifluo
Biological ActivityPlasminogen activator inhibitor-1 (PAI-1) inhibitor (IC50 = 2.7 μM). Induces vascular smooth muscle cell apoptosis in vitro and reduces carotid artery neointimal formation in a rat vascular injury model. Promotes thrombolysis in rat and dog models of acute arterial thrombosis. Orally available.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Simone et al (2015) A small molecule PAI-1 functional inhibitor attenuates neointimal hyperplasia and vascular smooth muscle cell survival by promoting PAI-1 cleavage. Cell.Signal. 27 923. PMID: 25617690.
Elokdah et al (2004) Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J.Med.Chem. 47 3491. PMID: 15214776.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Tiplaxtinin from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Tiplaxtinin, supplier, thrombolysis, thrombolytic, PAI-1, plasminogen, activator, inhibitors, inhibits, apoptosis, inducers, induces, orally, available, PAI039, Tocris Bioscience, Other Protease Inhibitor products
Find multiple products by catalog number
New Products in this Area
High affinity angiotensin-converting enzyme (ACE) ligandTMI 1
Adam 17 (TACE) and MMP inhibitor; orally bioavailableRitonavir
HIV-1 and HIV-2 protease inhibitorAcetyl Pepstatin
High affinity aspartic protease inhibitor; inhibits HIV-1/2 proteinasesONO 6818
High affinity and selective human neutrophil elastase 1 (HNE1) inhibitor; orally active
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.